Foghorn Therapeutics Shares Outstanding History (FHTX)
Foghorn Therapeutics reported 56.7M shares outstanding at the end of fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 56.7M | 1.1M | +1.91% |
| 2024 | 2024-12-31 | 55.6M | 13.3M | +31.48% |
| 2023 | 2023-12-31 | 42.3M | 478,604 | +1.14% |
| 2022 | 2022-12-31 | 41.8M | 503,716 | +1.22% |
| 2021 | 2021-12-31 | 41.3M | 4.5M | +12.26% |
| 2020 | 2020-12-31 | 36.8M | 31.9M | +655.33% |
| 2019 | 2019-12-31 | 4.9M | — | — |
Foghorn Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 58.7M | 2.9M | +5.22% |
| Q1 2026 | 2026-03-31 | 58.7M | 3.0M | +5.36% |
| Q4 2025 | 2025-12-31 | 56.7M | 1.1M | +1.91% |
| Q3 2025 | 2025-09-30 | 56.5M | 949,746 | +1.71% |
| Q2 2025 | 2025-06-30 | 55.8M | 474,540 | +0.86% |
| Q1 2025 | 2025-03-31 | 55.7M | 13.1M | +30.85% |
| Q4 2024 | 2024-12-31 | 55.6M | 13.3M | +31.48% |
| Q3 2024 | 2024-09-30 | 55.6M | 13.4M | +31.68% |
| Q2 2024 | 2024-06-30 | 55.3M | 13.5M | +32.20% |
| Q1 2024 | 2024-03-31 | 42.6M | 760,858 | +1.82% |
| Q4 2023 | 2023-12-31 | 42.3M | 478,604 | +1.14% |
| Q3 2023 | 2023-09-30 | 42.2M | 417,758 | +1.00% |
| Q2 2023 | 2023-06-30 | 41.9M | 224,526 | +0.54% |
| Q1 2023 | 2023-03-31 | 41.8M | 395,143 | +0.95% |
| Q4 2022 | 2022-12-31 | 41.8M | 503,716 | +1.22% |
| Q3 2022 | 2022-09-30 | 41.8M | 4.8M | +12.83% |
| Q2 2022 | 2022-06-30 | 41.6M | 4.8M | +12.93% |
| Q1 2022 | 2022-03-31 | 41.4M | 4.6M | +12.50% |
| Q4 2021 | 2021-12-31 | 41.3M | 4.5M | +12.26% |
| Q3 2021 | 2021-09-30 | 37.0M | 31.0M | +515.24% |
| Q2 2021 | 2021-06-30 | 36.9M | 32.0M | +656.77% |
| Q1 2021 | 2021-03-31 | 36.8M | — | — |
| Q4 2020 | 2020-12-31 | 36.8M | — | — |
| Q3 2020 | 2020-09-30 | 6.0M | — | — |
| Q4 2019 | 2019-12-31 | 4.9M | — | — |
Foghorn Therapeutics shares outstanding trends
Over the last five reported fiscal years, Foghorn Therapeutics's shares outstanding moved from 36.8M to 56.7M, a change of 19.9M. The latest reported quarter, Q2 2026, shows 58.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics filings at SEC.gov ↗